Metabotropic glutamate receptors as therapeutic targets for schizophrenia
Authors:
- 1 March 2012
- journal article
- review article
- Published by Elsevier in Neuropharmacology
- Vol. 62 (3) , 1461-1472
Abstract
No abstract availableKeywords
This publication has 150 references indexed in Scilit:
- Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffoldBioorganic & Medicinal Chemistry Letters, 2011
- Functional interaction of mGlu5 and NMDA receptors in aversive learning in ratsNeurobiology of Learning and Memory, 2011
- Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockadeEuropean Journal of Pharmacology, 2010
- Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in ratsEuropean Journal of Pharmacology, 2010
- Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotionPsychopharmacology, 2010
- Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activationNeuroscience, 2010
- Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampusNeuropharmacology, 2009
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004
- Reduced Cortical Synaptic Plasticity and GluR1 Expression Associated with Fragile X Mental Retardation Protein DeficiencyMolecular and Cellular Neuroscience, 2002